Three different lawsuits have been filed against Bayer in which plaintiffs allege they were not warned of possible side effects in a drug used to control bleeding in coronary artery bypass grafting that caused some of the plaintiffs' family members to die.

All of the lawsuits were filed Sept. 22 in St. Clair County Circuit Court and allege the plaintiffs or their deceased relatives experienced renal damage, renal insufficiency and multi-system organ failure after their use of Trasylol.

Trasylol, which was approved by the FDA in 1993, is usually supplied as a colorless, sterile isotomic solution that is administered through an IV during coronary artery bypass grafting, according to the complaints.

"Trasylol is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of CABG procedures," the suits state. "The effects of Trasylol use in cardiopulmonary bypass surgery involve a reduction in inflammatory response, which translates into a decreased need for allogenic blood transfusions and reduced bleeding."

When Trasylol first appeared on the market, it included a warning about possible anaphylactic reactions, which are increased when patients have been exposed to aprotinin prior to their Trasylol use, the complaints say.

However, it provided no warnings about its link to renal toxicity, which was first revealed in an online "Transfusion" article dated Jan. 20, 2006, according to the complaints.

Another study was published in the "New England Journal of Medicine" on Jan. 26, 2006, reporting Trasylol's association with serious renal toxicity and ischemic events, the suits state.

The FDA began to evaluate the studies, and during its assessment, issued a warning to physicians to monitor patients for toxicity.

After a 19-member advisory panel studied the matter, it recommended to the FDA that Bayer's warnings on Trasylol did not need to be strengthened, the complaints say.

But just days after the panel's recommendation, a professor at Harvard's School of Public Health contacted the FDA about a 67,000 patient study he helped to perform at Bayer's request. The study confirmed that Trasylol increased the risk of renal failure, heart attack and stroke, the plaintiffs claim. In addition, it suggests that patients who receive Trasylol are at an increased risk of death, kidney failure and congestive heart failure.

Bayer knew of the study and its results, but failed to disclose the data to the FDA, according to the complaints.

Finally, on Dec. 15, 2006, the FDA approved revised labeling for Trasylol that specifies the drug should be given only to patients who are at an increased risk for blood loss and blood transfusion. The label also includes a warning that Trasylol increases the risk for kidney damage, according to the complaints.

Since Trasylol's approval, 4.3 million patients have been subjected to the potentially lethal drug, the plaintiffs claim. In 2005 alone, Trasylol generated about $293 million in sales, the complaints say.

Because of their exposure to Trasylol, the plaintiffs say they have suffered anxiety, distress, fear of death, pain, suffering and depression. In addition, their ability to enjoy life has greatly decreased, they sustained a loss of earnings and have incurred medical expenses, the suits state.

Of the lawsuits filed Sept. 22, the first complaint contains 19 plaintiffs; the second includes 18; and the third names 18.

These are not the first lawsuits to be filed in St. Clair County Circuit Court against Bayer for Trasylol use. On Aug. 20, Don Juan Brown and Jean N. Snyder also filed a nearly identical lawsuit against the drug maker.

In each of the 26-count suits, the plaintiffs allege defective design, strict product liability, intentional infliction of emotional distress, common law fraud, negligence, negligent misrepresentation and wrongful death.

In each of the suits, the plaintiffs are seeking judgments of more than $1.3 million, plus costs and other relief the court deems just.

All the plaintiffs will be represented by John J. Driscoll of Driscoll of St. Louis and by Christopher Cueto of Driscoll and Cueto in Belleville and by Robert L. Salim of Natchitoches, La.

St. Clair County Circuit Court case numbers:09-L-496, 09-L-497, 09-L-498.

More News